SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
analysts and calls -- ML
An SI Board Since September 2002
Posts SubjectMarks Bans
238 19 0
Emcee:  scaram(o)uche Type:  Moderated
Introduction Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
188NVS: Novartis (NVSEF/NVS; CHF70.70/$55.10, A-1-7/A-1-7) Reiterate Buy; Px tgt $tom pope-1/24/2006
187FRX: Forest Labs (FRX, $43.07, B-1-9) On 1/12, Upgraded From Neutral to Buy wittom pope-1/16/2006
186Thanks, Tuck. As far as <i>The biotech sector "is likely to be volatFiloF-12/19/2005
185From Forbes.com >>Biotech Picks And Pans For 2006 Kate DuBose Tomassie, tuck-12/19/2005
184Pharmas and IP Holiday Cheer for Intellectual Property Retaining Neutral Ratingtom pope-12/19/2005
183I thought it interesting that ML seems to be outsourcing the analyst function - tom pope-12/14/2005
182OT (sorry, Tom): I was outsourced quickly this morning by my wife. Actually, I&quidditch-12/14/2005
181Quid - you've never heard of outsourcing? :-)tom pope-12/14/2005
180Wonder why ML assigned him to write the report, or why it wasn't (ghost or quidditch-12/14/2005
179AFFX Affymetrix Inc  Coverage Resumed; A year of growing pains ahead Reinstatitom pope-12/14/2005
178ALKS - interesting disclaimer at bottom Alkermes Inc.  Price Objective Change tom pope-12/14/2005
177TEVA vs MYL Specialty Pharmaceuticals Relative Value: MYL Over TEVA Teva’s Outptom pope-12/13/2005
176AMGN - Ten questions? My coffee hasn't kicked in yet. (edit - I got it, the tom pope-10/31/2005
175Amgen Inc (AMGN, $78.09, C-1-9) Reiterate Buy and $104 PT. 3Q Results: Weak Saletom pope-10/20/2005
174CBST Cubist Pharmaceuticals Inc (CBST, $18.05, C-1-9) Reiterate Buy & $28 Ptom pope-10/20/2005
173SmallCap Strategy End of Year Bounce in the Making - Buy Lower Cap, Beta & Gtom pope-10/18/2005
172This from 9/28: DNA; $82.55; C-1-9 12-Month Price Objective: $103.00 (21-Sep-20tom pope-10/5/2005
171This is from 9/27: DNA; $85.83; C-1-9 12-Month Price Objective: $103.00 (21-Septom pope-10/5/2005
170Whisper number is 32 cents versus current consensus of 30 cents. earningswhispetuck-10/5/2005
169And KERX. Something goosed KERX today. Maybe this? Keryx Biopharmaceuticals (KEtom pope-10/3/2005
168Thanks, Doc, for reminding me that I hadn't checked ML today: COLY (COLY watom pope-10/3/2005
167Genentech Could Beat Q3 Earnings Estimates Peter Kang, 10.03.05, 12:20 PM ET Doc Bones-10/3/2005
166CBST Cubist Pharmaceuticals Inc (CBST, $19.55, C-1-9) Reiterate Buy, Raising Tatom pope-9/26/2005
165NVS Novartis  Company Update; R&D Update Increases Confidence in Forecaststom pope-9/21/2005
164JNJ Johnson & Johnson Our $75 price objective assumes JNJ trades at ~20x outom pope-9/6/2005
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News